Parkinnova Therapeutics
Parkinnova Therapeutics, focuses on developing novel treatments for midbrain dopamine disorders like Parkinson’s disease. The company targets the PDE11a pathway to upregulate dopamine production. Parkinnova aims to bring innovative therapies to clinical trials, addressing significant unmet needs in neurodegenerative diseases. The company is committed to advancing neuroscience through cutting-edge research.
InSteps
Providing in-silico modeling for stroke treatment, InSteps develops a platform to simulate various stroke scenarios. Their technology aids in the development of thrombectomy devices and optimizes clinical trials, giving more patients access to life-saving treatments. The company is committed to enhancing stroke care through advanced simulation technology.
GuanaRep
Repurposing the hypertension drug Guanabenz, GuanaRep aims to provide an affordable therapy for Vanishing White Matter, a rare neurological disease that mostly affects young children. Their research, led by Amsterdam UMC Professor Marjo van der Knaap, shows promising clinical results. GuanaRep focuses on making treatments accessible to patients worldwide.
Deep Sleep Technologies
Deep Sleep Technologies focuses on enhancing sleep quality and recovery. Their advanced technology addresses sleep disorders and optimizes restorative sleep. Deep Sleep Technologies aims to revolutionize sleep health with innovative, science-backed solutions. The company is committed to improving well-being through better sleep.
